fig4
![The <i>TNNI3</i> p.R186Q mutation is responsible for hypertrophic cardiomyopathy via promoting FASN-stimulated abnormal fatty acid metabolism](https://image.oaes.cc/77c8bd4b-4af1-454c-bb0d-654b20239147/5337.fig.4.jpg)
Figure 4. FASN inhibition attenuates TNNI3 p.R186Q-induced aberrant fatty acid metabolism and cardiac hypertrophy. Tnni3R186Q/R186Q mice at 10 months of age were administered saline or C75 (15 mg/kg/day) daily for 8 weeks. (A) Experiment timeline for